HALOHALOZYME THERAPEUTICS, INC.vs its industry peers
A metric-by-metric comparison of HALOZYME THERAPEUTICS, INC. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HALOEsta | $9.9B#8 | 29.2x#3 | 45.0x#11 | 7.1x#3 | 37.6%#8 | -28.6%#7 | 33.6%#3 | 144.3%#1 | 15.5%#1 | — | 38.7%#11 | — |
| MDGL | $11.7B#5 | — | 22.4x#8 | 12.2x#5 | 432.1%#2 | 38.1%#4 | -31.3%#6 | -55.0%#8 | -52.5%#4 | — | 62.1%#10 | — |
| TGTX | $7.5B#12 | 17.1x#1 | 12.8x#4 | 12.1x#4 | 87.3%#6 | 1811.1%#1 | 20.0%#4 | 76.7%#2 | 13.9%#2 | — | 69.8%#9 | — |
| INSM | $21.4B#2 | — | 30.4x#10 | 35.3x#8 | 66.7%#7 | -39.7%#9 | -205.6%#8 | -181.1%#11 | -185.1%#6 | 4#1 | -11.3%#14 | — |
| SRRK | $5.7B#15 | — | 20.8x#7 | — | — | -53.7%#11 | — | -137.0%#9 | -901.6%#7 | — | 29.6%#13 | — |
| APGE | $10.0B#7 | — | — | — | — | -40.5%#10 | — | — | — | — | 260.8%#3 | — |
| PTGX | $8.7B#10 | — | 13.3x#5 | 190.1x#10 | -89.4%#11 | -147.3%#13 | -343.6%#9 | -19.9%#5 | -33.5%#3 | — | 152.7%#5 | — |
| SMMT | $11.0B#6 | — | 17.4x#6 | — | — | -387.8%#14 | — | -171.4%#10 | — | — | -53.0%#15 | — |
| UTHR | $22.0B#1 | 19.2x#2 | 3.7x#1 | 6.9x#2 | 10.6%#9 | 11.7%#5 | 46.9%#2 | 22.6%#3 | — | — | 77.0%#7 | — |
| PRAX | $8.7B#11 | — | 6.1x#2 | — | -100.0%#12 | -65.6%#12 | — | -21.5%#6 | — | — | 508.0%#1 | — |
| ARWR | $12.7B#4 | — | 27.2x#9 | 15.3x#6 | 23258.2%#1 | 99.7%#3 | 11.9%#5 | -0.4%#4 | — | — | 444.9%#2 | — |
| COGT | $7.3B#13 | — | 12.1x#3 | 930.4x#11 | -65.0%#10 | -28.6%#6 | -4235.3%#11 | -54.1%#7 | -81.2%#5 | — | 255.1%#4 | — |
| BBIO | $16.1B#3 | — | — | 32.0x#7 | 126.3%#4 | — | -104.2%#7 | — | — | — | 71.8%#8 | 0.0%#1 |
| PTCT | $5.8B#14 | — | — | 3.3x#1 | 114.5%#5 | 288.0%#2 | 50.1%#1 | — | — | — | 32.2%#12 | — |
| CYTK | $9.8B#9 | — | — | 111.1x#9 | 376.6%#3 | -33.2%#8 | -695.4%#10 | — | — | — | 115.0%#6 | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-08-05.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice